Glycoengineered obinutuzumab activates PMNs in whole blood more efficiently than wild-type rituximab. Nonglycoengineered wild-type rituximab (WT-RTX) or glycoengineered obinutuzumab (GE-OBZ) at 10 µg/mL (panels A,B,E); 1, 10, or 100 µg/mL (panels D,C,F); or 0.1 µM of PMA were added to whole blood from healthy donors (panels A-C) or from patients with CLL (panels D-F). CD11b (panels A,D), CD62L (panels B,E), and ROS expression by PMNs (panels C,F) were analyzed after 24 hours, 6 hours, and 1 hour, respectively. The data are the means and standard deviations of 2 to 7 independent experiments, as indicated in each panel.